دورية أكاديمية
Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
العنوان: | Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials |
---|---|
المؤلفون: | Wang H, Wang HF, Yu ZC, Liu HH |
المصدر: | OncoTargets and Therapy, Vol Volume 11, Pp 5195-5201 (2018) |
بيانات النشر: | Dove Medical Press, 2018. |
سنة النشر: | 2018 |
المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | sorafenib, tyrosine kinase inhibitors, selective internal radiotherapy, hepatocellular carcinoma, meta-analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Hui Wang, Hefang Wang, Zhichong Yu, Honghao Liu Department of Radiation Oncology, Yancheng First People’s Hospital, Yancheng, Jiangsu 224005, China Introduction: This meta-analysis was conducted to evaluate efficacy and safety in patients treated with sorafenib vs other tyrosine-kinase inhibitors (TKIs) or selective internal radiotherapy (SIRT) for advanced hepatocellular carcinoma (HCC).Methods: Electronic databases were systematically reviewed for randomized Phase III trials comparing sorafenib with other TKIs or SIRT in advanced HCC. Sorafenib was defined as the control arm. Other TKIs or SIRT was defined as the experimental arm. Overall survival (OS), time to progression (TTP), objective response rate (ORR), disease-control rate (DCR), and adverse events (AEs) were reviewed. Four trials in the other-TKI group (n=4,218) and two in the SIRT group (n=819) were eligible.Results: Compared with sorafenib, other TKIs showed similar benefit on OS (HR 1.08, 95% CI 0.93–1.24; P=0.31) and TTP (HR 0.86, 95% CI 0.66–1.12; P=0.26) for advanced HCC. A significant increase in ORR (RR 1.67, 95% CI 1.15–2.43; P=0.008) was found with other TKIs, but no increase in DCR (RR 1.11, 95% CI 0.98–1.26; P=0.11) was observed. Other TKIs were associated with more frequent grade 3/4 AEs than sorafenib, including hypertension (P |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1178-6930 63013568 |
Relation: | https://www.dovepress.com/alternative-treatment-strategies-to-sorafenib-in-patients-with-advance-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930 |
URL الوصول: | https://doaj.org/article/7a8d80636d5f4b39b15e63013568ae33 |
رقم الأكسشن: | edsdoj.7a8d80636d5f4b39b15e63013568ae33 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 11786930 63013568 |
---|